MedTrace Logo

Translational Research in Identifying Molecular Mechanisms for Rectal Cancer Metastasis

NCT02979795 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2016-12-02

No results posted yet for this study

Summary

Rectal cancer, comprised of 30% of overall colorectal cancer cohort, is one of the leading cancers of Taiwan. In patients with advanced disease, the standard of care is concurrent chemoradiotherapy (CCRT) before surgery. After CCRT, the abscopal effect, a phenomenon that localized radiation not only destroys local tumor but also inhibits the growth of tumor at the remote site, has been observed. This effect is believed to be associated with tumor immune response. In addition, other immune checkpoint molecules, such as Programmed cell death-1(PD-1), Programmed cell death ligand-1 (PD-L1), and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), have been reported associated with therapeutic outcome. However, after CCRT, more than 50% of patients were still either having persistent disease or developed distant metastasis. To improve therapeutic outcome of patients with rectal cancer, this project, thus, aims at exploring the evolution of factors that may affect the abscopal effect and immune checkpoint functions in tissues and in blood before and after CCRT.

Conditions

Interventions

PROCEDURE

Preoperative chemoradiotherapy

Preoperative chemoradiotherapy. 2.5 Gray/fraction (Total in 45-54 Gray)

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Kan Sun Clifford Chao, MD · China Medical University Hospital

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2020-11-30
Completion
2020-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02979795 on ClinicalTrials.gov